EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review

Jacques Donnez iD, Olivier Donnez, Hugh S Taylor, Felice Petraglia, Andrew W Horne iD, Christian M Becker, Stefan P Renner, Marionna Rius, Elke Bestel, Christina Anna Stratopoulou, Marie-Madeleine Dolmans iD

Reproduction and Fertility · 2026

DOI: 10.1530/raf-26-0075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reproduction and Fertility, 2026. Verfasst von Jacques Donnez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Université Catholique de Louvain , Brussels, Belgium. Hauptthemen laut MEDLINE: Adenomyosis, Gonadotropin-Releasing Hormone, Hormone Antagonists. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abstract In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly a widespread demand for effective long-term medical therapies. The objective of this narrative review was to investigate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists in the management of uterine adenomyosis by analyzing data from two post hoc analyses of two prospective randomized trials (elagolix and relugolix), one retrospective study (relugolix) and one prospective study (linzagolix). All three GnRH oral antagonists were able to control the disease and uterine fibroid-related heavy menstrual bleeding, enhancing quality of life. When administered without add-back therapy, high doses of GnRH antagonists were found to significantly and rapidly reduce uterine volume and the severity of adenomyotic lesions. Nevertheless, some limitations should be addressed. The post hoc analyses were a retrospective look at two prospective randomized clinical trials. In the elagolix study, most women underwent both transvaginal ultrasound and magnetic resonance imaging (MRI). Some who opted out of MRI may have had concurrent adenomyosis that was undetected by ultrasound, so they were not included in the adenomyosis subset. In the relugolix study, baseline ultrasounds were not specifically performed to spot adenomyosis that may have been overlooked in case of large fibroids, as shadowing can partially or completely obscure the disease. While the linzagolix study is prospective and evaluates data from women with proven adenomyosis documented by MRI, the number of cases is limited and randomized controlled trials are needed to confirm and validate this concept. Lay summary Uterine adenomyosis is characterized by the presence of endometrial glands inside the myometrium, the muscular layer of the uterus. Transvaginal ultrasound and magnetic resonance imaging now facilitate its diagnosis. The estimated prevalence of adenomyosis among patients of reproductive age is 20–30%. Rising rates in younger patients combined with a growing trend to postpone first pregnancy underscore the importance of understanding the mechanisms behind its development. We need novel strategies for the treatment of typical but distressing symptoms of adenomyosis, which include pelvic pain, abnormal uterine bleeding, menstrual cramps, painful sex and infertility. There is a lack of approved pharmacological agents specifically indicated for the treatment of adenomyosis, presenting a clear unmet need in this population. Oral gonadotropin-releasing hormone (GnRH) antagonists have recently emerged as a promising new therapeutic option. Their advantages over GnRH agonist depot formulations include an absence of the flare-up effect, hence avoiding initially worsening symptoms and rapid reversibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomyosisGonadotropin-Releasing HormoneHormone AntagonistsHumansFemaleAdministration, OralPyrimidinesPyrimidinonesHydrocarbons, FluorinatedPhenylurea Compounds

Stichwörter der Autor:innen

GnRH antagonistadenomyosiselagolixheavy menstrual bleedinglinzagolixpainquality of liferelugolix

Substanzen

Gonadotropin-Releasing HormoneHormone AntagonistsPyrimidineselagolixPyrimidinonesHydrocarbons, FluorinatedrelugolixPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Gynecology, Université Catholique de Louvain , Brussels, Belgium.
  • Department of Gynecology, Société de Recherche pour l'Infertilité (SRI) , Brussels, Belgium.
  • Centre de l'Endométriose Complexe, Chirurgie Endoscopique Pelvienne, Polyclinique Urbain V (ELSAN Group) , Avignon, France.
  • Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine , New Haven, Connecticut, USA.
  • Obstetrics and Gynecology Unit, Department of Clinical Experimental and Biomedical Sciences, University of Florence , Florence, Italy.
  • EXPPECT Edinburgh Centre for Reproductive Health, University of Edinburgh , Edinburgh, UK.

ORCID-Profile: Jacques Donnez, Andrew W Horne, Marie-Madeleine Dolmans

Zitieren

APA

Donnez, J., Donnez, O., Taylor, H. S., Petraglia, F., Horne, A. W., Becker, C. M., Renner, S. P., Rius, M., Bestel, E., Stratopoulou, C. A., & Dolmans, M. M. (2026). Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review. Reproduction and Fertility. https://doi.org/10.1530/raf-26-0075

Vancouver

Donnez J, Donnez O, Taylor HS, Petraglia F, Horne AW, Becker CM, et al. Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review. Reproduction and Fertility. 2026. doi:10.1530/raf-26-0075

BibTeX
@article{Donnez2026,
  author = {Donnez, Jacques and Donnez, Olivier and Taylor, Hugh S and Petraglia, Felice and Horne, Andrew W and Becker, Christian M and Renner, Stefan P and Rius, Marionna and Bestel, Elke and Stratopoulou, Christina Anna and Dolmans, Marie-Madeleine},
  title = {Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review},
  journal = {Reproduction and Fertility},
  year = {2026},
  doi = {10.1530/raf-26-0075}
}
Kostenlos starten →